Worldwide Alzheimer's Drugs Market 2018 : Size, Revenue & Growth Analyzed adds report Global Alzheimer's Drugs Market 2014-2018 to its store. The incidence rates for Alzheimer's disease are increasing, and the global Alzheimer's population is expected to double by 2030. Currently, it is estimated that 5 million Americans suffering from Alzheimer's disease are aged 65 years or above. This number might reach 13.8 million by 2050 as the baby boom generation ages. In the US, Alzheimer's disease is the fifth highest cause factor for deaths among people aged 65 years and above. It has been recognized as the only factor among the top 10 death-causing factors in America for which therapy is not available, preventing or slowing down the progression of disease. The number of deaths resulting from Alzheimer's disease increased by 68 percent during the period of 2000-2010 and this number is expected to increase further during the next decade. In the US, it is estimated that about 7,00,000 people aged 65 years or above will die from Alzheimer's disease in 2014. The incidence rate of Alzheimer's disease is increasing rapidly owing to a rise in the elderly population. In the US, the 2014 incidence rate of Alzheimer's disease for people aged 65 years or above is expected to reach 4,69,000 and this number is expected to double by 2050.

According to the report, the Global Alzheimer's Drugs market is driven by several factors, of which the increase in the global aging population is one of the major drivers. The incidence of Alzheimer's disease is growing continuously, mainly because of an increase in the aging population, especially those aged 65 years or above. It is estimated about 596.8 million people will reach 65 years and above in 2014, and this number is expected to reach 681.2 million by 2018.

Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.

Analysts forecast the Global Alzheimer's Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Alzheimer's Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer's disease.

Purchase Report Directly @

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer's Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Global Alzheimer's Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer's Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC
Analyst recognizes the following companies as the key players in Global Alzheimer's Drugs Market: Eisai Co., Ltd., Forest Laboratories Inc., Janssen Pharmaceuticals Inc., Novartis AG, Adamas Pharmaceuticals Inc., Archer Pharmaceuticals Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Merck & Co., Inc., MorphoSys AG, Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical, Inc., Takeda Pharmaceutical Co., Ltd., TauRx Pharmaceuticals Ltd., Zinfandel Pharmaceuticals Inc.

Key Market Driver
  • Increasing Aging Population

Key Market Challenge

  • Poor Diagnosis of Alzheimer's Disease

Key Market Trend

  • Increasing Incidence, Prevalence, and Mortality of Alzheimer's Disease

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

About Us: is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on and we would be happy to help you find the business intelligence that you need. Not limited to the Pharmaceuticals Market offers research studies on agriculture, consumer goods, environment, advanced materials, public sector, food and beverages, energy and power, medical devices, healthcare, automotive, manufacturing & construction, semiconductor and electronics, IT & telecommunication, pharmaceuticals, retail, water, banking and financial services , advanced materials and much more.